The influence of electrical high-speed rotation on mandibular third molar surgeries: a prospective, randomized, split-mouth clinical and radiographic study.

The aim of this split-mouth randomized clinical trial was to evaluate the clinical outcomes (operative time, edema, trismus, and pain), the immediate histological effects, the alveolar repair (2 and 4 months), and the quality of life after the extraction of impacted third molars using high-speed pneumatic and electrical rotation. Sixteen patients underwent extraction of the two mandibular third molars with a minimum interval of 15 days. On one side of the participant's mouth, high-speed pneumatic rotation was used (Control Group-CG) while for the other side, high-speed electrical rotation was used (Study Group-SG). Statistical analysis included ANOVA repeated measures and Pearson correlations. SG group showed: shorter operative time (p = 0.019), less pain (p = 0.034), swelling (p < 0.001) and trismus (p = 0.025) on the 1st postoperative day; less pain (p = 0.034) and trismus (p = 0.010) on the 3rd postoperative day; less trismus (p = 0.032) on the 7th postoperative day; and better quality of life (p = 0.007). No differences were observed for peripheral bone damage or bone density of alveolar repair at 2 and 4 months between groups. Electric high-speed rotation provided better postoperative clinical parameters of pain, edema and trismus when compared with pneumatic high-speed rotation for mandibular third molar surgery.Trial registration: Brazilian Registry of Clinical Trials registration number RBR-4xyqhqm ( https://ensaiosclinicos.gov.br/rg/RBR-4xyqhqm ).

Comparative study of the effect of different temperatures on bovine bone used for bone repair of critical calvaria defects in rats.

To evaluate the osteoconductive potential of inorganic biomaterials of bovine origin submitted to different temperatures in the bone repair of critical defects in rat calvaria. Forty-eight rats were divided into four groups according to the material used to fill the defect: control group (GC), the defect was filled only with blood clot (n = 12); GBO, defect filled with Bio-Oss®, deproteinzed at 300°C (n = 12); GOX, defect filled with Inorganic GenOx®, deproteinzed from 850 to 1200°C (n = 12) and G700, defect filled with Inorganic GenOx 700, deproteinzed at 700°C (n = 12). In each animal's calvaria, a trephine bur with 5 mm internal diameter was used to produce a 6 mm-diameter central defect. Gen Derm® resorbable bovine membrane was superimposed over all defects. Subsequently, animals were euthanized at 30 and 60 days after surgery. The pieces were sent for histological and histometric analysis to evaluate the following variables: bone neoformation, presence of biomaterial, mononuclear and polymorphonuclear leukocytes, presence of other tissues (granulation and medullary) and maturation of collagen fibers. The most representative group for bone neoformation was GC. At 30 days, there was a higher mean of mature bone tissue (75.8). At 60 days, there was no statistical difference between the GC (64.9), GBO (32.9), GOX (45.3), and G700 (26.6) groups. GBO presented the highest amount of biomaterial after 30 days (115.9) and 60 days (118.5). All bovine biomaterials were biocompatible and osteoconductive. GOX promoted the best bone repair of the studied materials.

Sucesso de implantes osseointegráveis em pacientes hipertensos: estudo retrospectivo de 17 anos / Success of osseointegrated implants in hypertensive patients: retrospective study of 17 years

O objetivo deste estudo foi relacionar a hipertensão e medicamentos antihipertensivos com o insucesso dos implantes osseointegrados. Foram analisados dados de 602 prontuários de pacientes que receberam tratamento reabilitador com implantes ossseointegrados no período de 2000 a 2017, concluído no mínimo há 6 meses. Foram coletados dados de idade, gênero, presença ou não de hipertensão, uso ou não antihipertensivos, número de implantes instalados e perdidos e tipo de prótese confeccionada. Testes estatísticos de qui-quadrado e teste exato de Fisher foram utilizados para relacionar as variáveis com a perda de implante, com nível de significância de p< 0,05. Foram instalados 1887 implantes com índice de sucesso de 97,51%(47 implantes perdidos em 41 pacientes). Dos 602 pacientes, 71,43 %(432) não apresentavam hipertensão e 28,36% (171) eram hipertensos. A taxa de sucesso dos implantes no grupo de normotensos foi de 93,28% e no grupo de hipertensos foi de 92,99%, não havendo diferença estatística entre eles (P= 0,958). Destes pacientes, as taxas de sucesso foram semelhantes para usuários de medicação (92,5%) e para não usuários (94,1%), não havendo diferença estatística relevante (P= 0,939). A presença da hipertensão, assim como o uso de antihipertensivos não puderam ser associadas ao insucesso dos implantes osseointegrados(AU)

The aim of this study was to relate hypertension and antihypertensive drugs to the failure of osseointegrated implants. Were analyzed 602 medical records of patients who received rehabilitation treatment with osseointegrated implants between 2000 and 2017, completed at least 6 months ago. Age, gender, presence or absence of hypertension, use or not antihypertensive drugs, number of installed and lost implants and type of prosthesis made were collected. Statistical chi-square tests and Fisher's exact test were used to relate the variables with implant loss, with a significance level of p < 0.05. 1,887 implants were installed with a success rate of 97.51% (47 implants lost in 41 patients). Of the 602 patients, 71.43% (432) did not have hypertension and 28.36% (171) were hypertensive. The success rate of implants in the normotensive group was 93.28% and in the hypertensive group it was 92.99%, with no statistical difference between them (P = 0.958). Of these patients, the success rates were similar for medication users (92.5%) and for non-users (94.1%), with no statistically significant difference (P = 0.939). The presence of hypertension, as well as the use of antihypertensives, could not be associated with the failure of osseointegrated implants(AU)